NDA 217639 · Stemline Therap
Orserdu
Elacestrant Hydrochloride · Oral · Estrogen Receptor Antagonist
NovelPriority reviewCDER novel approval, Jan 27, 2023: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jan 27, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
39
5 Phase 3, 23 recruiting
FAERS reports
7,181
2,423 serious, 553 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Therapeutic areas: Oncology · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
2 products under this application
- ORSERDU · ELACESTRANT HYDROCHLORIDE EQ 86MG BASE · TABLET, ORAL · Prescription
- ORSERDU · ELACESTRANT HYDROCHLORIDE EQ 345MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elacestrant" as an intervention, any sponsor and status, largest first.
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePivotal-lookingActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT06492616 · 4,556 participants · Start Sep 27, 2024 · Primary completion Aug 2029
Drug: Elacestrant; Anastrozole and 3 more · For: Breast Cancer
Sites: Daphne, Alabama; Chandler, Arizona; Gilbert, Arizona · 555 sites in all
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCPivotal-lookingRecruiting
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT07242352 · 1,520 participants (planned) · Start Apr 29, 2026 · Primary completion Sep 30, 2033
Drug: Elacestrant; Standard-of-care endocrine treatment · For: Breast Cancer; HR+/HER2- Breast Cancer
Sites: Mannheim, Germany; Tübingen, Germany; Esslingen am Neckar, Germany · 33 sites in all
- Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPivotal-lookingCompleted
Stemline Therapeutics, Inc.Industry
NCT03778931 · 478 participants · Start May 10, 2019 · Primary completion Aug 24, 2021
Drug: Elacestrant; Standard of Care · For: Breast Cancer
Sites: Tucson, Arizona; Jonesboro, Arkansas; Fullerton, California · 244 sites in all
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT05563220 · 435 participants (planned) · Start Jan 24, 2023 · Primary completion Dec 27, 2026
Drug: Elacestrant; Alpelisib and 5 more · For: Breast Cancer; Metastatic Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Springdale, Arkansas · 83 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06120283 · 433 participants (planned) · Start Dec 1, 2023 · Primary completion Dec 2029
Drug: BGB-43395; Fulvestrant and 3 more · For: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer and 5 more
Sites: Denver, Colorado; Lake Mary, Florida; Detroit, Michigan · 61 sites in all
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT06075953 · 400 participants (planned) · Start Feb 17, 2024 · Primary completion Nov 2028
Drug: Tamoxifen; Exemestane and 5 more · For: Ductal Carcinoma in Situ
Sites: Berkeley, California; Duarte, California; Irvine, California · 31 sites in all
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Pivotal-lookingRecruiting
MedSIRAcademic, hospital or other
NCT06382948 · 300 participants (planned) · Start Dec 5, 2024 · Primary completion Sep 2027
Drug: Everolimus; Elacestrant and 3 more · For: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 1 more
Sites: Innsbruck, Austria; Linz, Austria; Schwaz, Austria · 104 sites in all
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Pivotal-lookingRecruiting
Kristina A. FanucciAcademic, hospital or other
NCT07222215 · 297 participants (planned) · Start Jan 16, 2026 · Primary completion Dec 1, 2029
Drug: Capecitabine; Elacestrant · For: Estrogen-receptor-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer and 6 more
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,512
- fatigue1,130
- disease progression783
- vomiting694
- diarrhoea566
- death520
- drug ineffective491
- constipation408
- product dose omission issue382
- decreased appetite377
- pain374
- arthralgia342
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3,022 |
| 2024 | 3,662 |
| 2025 | 330 |
| 2026 | 162 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orserdu (Elacestrant HCl)
2024 spending
$259M
Beneficiaries
2,633
11,378 claims
Per beneficiary
$98,308
$703.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $127,626,022 |
| 2024 | $258,846,198 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Bardia A, Cortés J, Bidard FC, et al. · Clin Cancer Res 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.
Shah M, Lingam H, Gao X, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Multicenter Study
- Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis.
Sarfraz A, Sarfraz M, Javad F, et al. · Explor Target Antitumor Ther 2025 · Systematic Review
- Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Conlan MG, de Vries EFJ, Glaudemans A, et al. · Eur J Drug Metab Pharmacokinet 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
- Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.
Vidal M, Falato C, Pascual T, et al. · Clin Cancer Res 2025 · Clinical Trial, Multicenter Study
Sponsor: Stemline Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.